We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Infusion Laboratory: Protocol 3 (Risperidone) - 4

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000339
Recruitment Status : Unknown
Verified June 1996 by National Institute on Drug Abuse (NIDA).
Recruitment status was:  Active, not recruiting
First Posted : September 21, 1999
Last Update Posted : January 11, 2017
Sponsor:
Information provided by:

September 20, 1999
September 21, 1999
January 11, 2017
June 1996
Not Provided
  • Evidence of change in neurotoxicity based on chore
  • Degree of drug craving
  • History, incidence and amount of drug use
  • Type and severity of stimulant withdrawal symptoms
  • Characterization of study population
  • Population incidence of symptoms of depression, po
  • Frequency and intensity of drug use and sexual beh
  • Evidence of change in subjective responses to coca
  • Clinical physiological response to cocaine challen
  • Degree to which study medication influences change
  • History, incidence and amount of drug use
  • Type and severity of stimulant withdrawal symptoms
  • Characterization of study population
  • Population incidence of symptoms of depression, po
  • Frequency and intensity of drug use and sexual beh
  • Evidence of change in subjective responses to coca
  • Clinical physiological response to cocaine challen
  • Degree to which study medication influences change
  • Degree of drug craving
  • Evidence of change in neurotoxicity based on chore
Complete list of historical versions of study NCT00000339 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Infusion Laboratory: Protocol 3 (Risperidone) - 4
Infusion Laboratory: Protocol 3 (Risperidone)
The purpose of this study is to evaluate clinical safety issues pertaining to risperidone, to cocaine and to its interaction, and to determine how pretreatment with risperidone modifies the subjective as well as physiological effects of cocaine.
Not Provided
Interventional
Phase 1
Intervention Model: Crossover Assignment
Masking: Single
Primary Purpose: Treatment
Cocaine-Related Disorders
Drug: Risperidone
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
13
Not Provided
Not Provided

Inclusion Criteria:

M/F ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.

Sexes Eligible for Study: All
21 Years to 50 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00000339
NIDA-3-0010-4
Y01-3-0010-4
Not Provided
Not Provided
Not Provided
Not Provided
National Institute on Drug Abuse (NIDA)
Not Provided
Principal Investigator: Walter Ling, M.D. Friends Research Institute, Inc.
National Institute on Drug Abuse (NIDA)
June 1996

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP